Indivior Pharmaceuticals Inc
NASDAQ:INDVDrug Manufacturers - Specialty & Generic
+$0.26 today
- Market cap
- $4.53B
- Beta
- 1.17
- P/E (TTM)
- 19.1
- EPS (TTM)
- $2.00
Volume 3.65M
Average 2.08M
INDV Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Indivior Pharmaceuticals IncNASDAQ: INDV
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin dips below year-ago levels
Q2 FY2026 selling, general & admin of $122M fell 22.8% year over year, behind the +18.4% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at +10.6% a year.
Context
- Selling, general & admin amounted to 51.2% of revenue in FY2025, down 0.8 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $697.39M (+10.0%) for the fiscal year ending Dec 2026, a step up from the +2.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $122M-1.6% QoQ
- Last fiscal yearDec 2025
- $634M+2.6% YoY
- LTMJun 2026
- $534M+18.4% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 634M USD
- Year-over-year change
- +2.6%
- 4-year CAGR
- +10.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 634M | +2.6% |
| FY2024 | 2024-12-31 | 618M | +8.6% |
| FY2023 | 2023-12-31 | 569M | +21.3% |
| FY2022 | 2022-12-31 | 469M | +8.8% |
| FY2021 | 2021-12-31 | 431M | — |
Selling, General & Admin vs competitors
How INDV compares with its peers on the latest reported figures
- INDV's LTM Jun 2026 selling, general & admin of $534M is the 3rd highest of the 4 companies compared; the peer median is $560.88M.
- Its year-over-year change of +18.4% is the 3rd highest of 4, against a peer median of +33.2%.
- Selling, general & admin amounts to 40.1% of revenue for INDV, versus a peer median of 50.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $881.19M | +33.2% | +6.5% | 50.3% | |
| LTM Jun 2026 | $560.88M | +68.6% | +8.8% | 67.5% | |
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $534M | +18.4% | +10.6% | 40.1% |
| LTM Mar 2026 | $206.83M | -15.5% | +17.1% | 26.0% | |
| Peer median (excluding INDV) | $560.88M | +33.2% | +8.8% | 50.3% | |
Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 791M | 901M | 1.09B | 1.19B | 1.24B |
| Cost of Revenue | 127M | 151M | 174M | 231M | 246M |
| Gross Profit | 664M | 750M | 919M | 957M | 993M |
| Gross Margin | 83.9% | 83.2% | 84.1% | 80.6% | 80.1% |
| Research & Development | 52M | 74M | 116M | 107M | 97M |
| Selling, General & Admin | 431M | 469M | 569M | 618M | 634M |
| Operating Expenses | 451M | 831M | 1.08B | 925M | 728M |
| Depreciation & Amortization | 22M | 16M | 15M | 28M | 20M |
| EBITDA | 238M | (46M) | (99M) | 83M | 304M |
| EBITDA Margin | 30.1% | -5.1% | -9.1% | 7.0% | 24.5% |
| Operating Income | 213M | (81M) | (156M) | 32M | 265M |
| Operating Margin | 26.9% | -9.0% | -14.3% | 2.7% | 21.4% |
| Interest Income | 4M | 19M | 43M | 23M | 22M |
| Interest Expense | 26M | 29M | 35M | 41M | 45M |
| Other Income / Expenses | (23M) | (8M) | 7M | (18M) | (26M) |
| Income Before Tax | 190M | (89M) | (149M) | 14M | 239M |
| Pre-Tax Margin | 24.0% | -9.9% | -13.6% | 1.2% | 19.3% |
| Income Tax Expense | (15M) | (44M) | (20M) | 11M | 29M |
| Net Income | 205M | (44M) | (129M) | 2M | 210M |
| Net Margin | 25.9% | -4.9% | -11.8% | 0.2% | 16.9% |
| EPS (Basic) | 1.38 | (0.37) | (0.94) | 0.02 | 1.68 |
| EPS (Diluted) | 1.31 | (0.37) | (0.91) | 0.02 | 1.64 |
| Weighted Avg Shares | 145.66M | 139.01M | 137.31M | 132M | 125M |
| Weighted Avg Shares (Diluted) | 154.23M | 139.01M | 141.8M | 133M | 128M |
Indivior Pharmaceuticals Inc
NASDAQ:INDV
Intrinsic Alpha fair value
Locked
Current Price
$36.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.